FluoroPharma Medical, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company has two clinical-stage molecular imaging pharmaceutical product candidates, such as CardioPET and BFPET. Additionally, it has identified potential candidates that might be useful in the detection and/or treatment of vulnerable plaque. Product Candidates BFPET The company’s BFPET ((18F)-labeled cationic lipophilic tetraphosphonium) is an imaging agent used in stress-testing for patients with presumptive or proven cardiac artery disease (CAD). BFPET measures the cardiovascular blood flow through the detection of ischemic (reversibly damaged) and infarcted (irreversibly damaged) myocardium (heart) tissue. BFPET completed the Phase Ia clinical trial in 12 healthy volunteers. The results of the trial demonstrated the required dosimetry, safety profile and high resolution myocardial imaging pharmacokinetics to justify a controlled Phase II clinical trial. In January 2013, the company announced that it would begin Phase II trials at Massachusetts General Hospital to assess its efficacy in CAD subjects. CardioPET The company’s CardioPET (Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid) is a molecular imaging agent to assess myocardial metabolism for patients with CAD, primarily for patients who are unable to perform exercise cardiac stress-testing. CardioPET allows for the detection of ischemic (reversibly damaged) and infarcted (irreversibly damaged) myocardium (heart) tissue in patients with presumptive or proven acute and chronic CAD. In addition, CardioPET could be used for cardiac viability assessment for the prediction of improvement prior to and/or following revascularization in patients with acute CAD, including myocardial infarction (heart attack). CardioPET has completed Phase I trials and is enrolling patients in its Phase II trials to assess its safety and efficacy in CAD subjects. VasoPET The company is developing VasoPET, Diadenosine-5’5’’’-P1, P4-tetraphosphate (Ap4A) analogs, such as P2, P3-monochloromethylene diadenosine 5’, 5’’’-P1, P4-tetraphosphate (Ap2CHClp2A), as novel molecular imaging agent for the detection of ‘vulnerable’ coronary artery plaque in patients with CAD. Business Strategy The company’s business strategy is to seek regulatory approval for BFPET, CardioPET, and VasoPET in the United States, and selectively in other countries; develop its own specialty sales and marketing teams to market BFPET, CardioPET, and VasoPET in the United States; expand the indications for which BFPET, CardioPET, and VasoPET might be used; advance the development of its preclinical product candidates; and expand its product pipeline through its proprietary platform technologies, acquisitions, and strategic licensing arrangements. History FluoroPharma Medical, Inc. was founded in 2003.
fluoropharma medical inc (FPMI:OTC US)
8 Hillside Avenue
Montclair, NJ 07042
|No competitor information is available for FPMI.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact FLUOROPHARMA MEDICAL INC, please visit www.fluoropharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.